Global Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research
According to a new market report published by Transparency Market Research “Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi, VisibiliT and Others) - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2014 – 2022”, the global NIPT market was valued at USD 0.53 billion in 2013 and is expected to expand at a CAGR of 17.5% from 2014 to 2022 to reach USD 2.38 billion in 2022.
Browse the full Non-invasive Prenatal Testing (NIPT) Market Report: http://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html
Non-invasive prenatal tests help in the detection of chromosomal aneuploidies (trisomy 18, trisomy 21, trisomy 13, monosomy X, etc.). Increasing demand for non-invasive prenatal tests is attributed to several benefits such as safety, sensitivity, and no risk of miscarriage during genetic screening. Increasing preference for late pregnancy (35 years and above) due to lifestyle and consistent modifications in the tests drive market growth. Advanced maternal age increases the risk of developing a fetus with certain chromosomal aneuploidies, thereby creating a huge demand for non-invasive prenatal tests. On the other hand, factors such as regulatory guidelines and ethical hurdles along with the need for invasive confirmatory prenatal tests could hamper market growth. The NIPT market could face ethical and regulatory hurdles associated with the implementation of NIPT because of the belief that it is likely to increase the incidence of abortions. Therefore, various professional organizations such as the American College of Obstetricians and Gynecologists (ACOG), the International Society for Prenatal Diagnosis and the Japan Society of Obstetrics and Gynecology, and genetic counselors around the world have strongly recommended the use of NIPT only in case of high-risk pregnancy.
According to the Centers for Disease Control and Prevention (CDC), nearly 700,000 pregnant women in the U.S. are at high risk of producing a child with chromosomal aneuploidies every year, representing a potential population base for NIPT. There are approximately 3.9 million births annually in the U.S. and approximately 377,886 births in Canada, representing target population for tests such as Harmony, Panorama, and VisibiliT.
Geographically, North America was the largest market for NIPT in 2013, accounting for a share of 58.8% in terms of revenue, followed by Asia Pacific. Significant presence of four major companies in the U.S. and launch of first NIPT in the country contributed to North America’s dominance in the NIPT market. MaterniT21 test was the first non-invasive prenatal test launched in the U.S. by Sequenom, Inc. and has recorded highest revenue and volume in North America compared to other tests. BambniTest was introduced by Berry Genomics, and the recent CFDA approval for the test would boost the growth of this test in Asia Pacific, both in terms of value and volume. InformaSeq non-invasive test was introduced by LabCorp in the U.S in 2014. Presently, this test is available only in the U.S. and is likely to be launched in other countries in the near future.
Browse the full Press Release of Non-invasive Prenatal Testing (NIPT) Market: http://www.transparencymarketresearch.com/pressrelease/noninvasive-prenatal-diagnostics-market.htm
The developers of NIPTs distribute these tests by collaborating with regional hospitals and diagnostic laboratories. Ariosa Diagnostics, Verinata Health (Illumina, Inc.), LabCorp, and Natera, Inc. are the major players operating in the NIPT market in North America. Increasing penetration by test developers in Europe, Asia-Pacific, and the Middle East indicates promising growth in these markets in the near future. BGI Diagnostics, LifeCodexx AG, Laboratoire Cerba, Natera, Inc., and Illumina Inc. have significant presence in Europe, while BGI Diagnostics and Berry Genomics dominate the NIPT market in Asia Pacific. NIPTs in countries such as Brazil and Mexico are available through hospitals and diagnostic laboratories such as Hospital Israelita Albert Einstein, DASA Group, and Fleury Group.
The global non-invasive prenatal testing market is segmented as follows:
Global Non-invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Test
- MaterniT21 PLUS
Global Non-invasive Prenatal Testing Market Revenue (USD Million) and Volume (Number of Tests Performed), by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)\
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453